The five awarded institutions have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.
The five awarded institutions have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.
IDSA seeks candidates to serve in the position of editor-in-chief of OFID. The founding editor-in-chief of the journal, Paul Sax, MD, FIDSA, recently departed for a new role as editor-in-chief of IDSA’s journal CID.
With rates of antimicrobial-resistant infections rising quickly, systemic changes are urgently needed to protect public health. This is no longer a future crisis but one that is at America’s doorstep and needs to be addressed now.
FDA’s decision to authorize state-licensed pharmacists to prescribe Paxlovid, within the limitations of and for those indications stated in the emergency use authorization, has the potential to expand access to timely treatment.
IDSA is pleased to see increased funding to strengthen the federal response to antimicrobial resistance, bolster the domestic and global fight against COVID-19, combat the infectious diseases impacts of the opioid crisis and strengthen global security in two recently passed appropriations bills.
As the term of Robert T. Schooley, MD, FIDSA, as editor-in-chief of Clinical Infectious Diseases ends, the Infectious Diseases Society of America wishes to thank him and all members of his editorial board for their extraordinary work as journal and Society leaders.
Increasing access to monkeypox testing and expanding vaccination against infection to people at high risk are needed and welcome steps in efforts to control spread and minimize symptoms.
Antimicrobial resistance — what infectious diseases experts warn could become the next pandemic — is poised to receive much needed federal investment.
IDSA and HIVMA condemn the U.S. Supreme Court decision overturning Roe v. Wade that sanctions government interference in patient autonomy and care and threatens the sanctity of the provider-patient relationship.
People who may be most in need of antiviral treatment for COVID-19 may not be receiving it because of where they live, according to a recent report from the U.S. Centers for Disease Control and Prevention.
IDSA supports the decision by the Food and Drug Administration and the Centers for Disease Control and Prevention to authorize the Pfizer-BioNTech and Moderna COVID-19 vaccines for young children and infants ages 5 years and younger.
IDSA in collaboration with CDC has selected 11 ID programs for the first Joint ID/CDC Epidemic Intelligence Service Fellowship. Each of the 11 programs will serve as options for the ID fellowship track for the joint IDSA and CDC training program.